The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1499
July 18, 2016
View Complete Issue         Table of Contents 2019 
SGLT2 Inhibitors and Renal Function
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
SGLT2 Inhibitors and Renal Function
July 18, 2016 (Issue: 1499)
At the same time that the FDA announced it was strengthening existing warnings about the risk of acute kidney injury in patients with type 2 diabetes treated with the sodium-glucose co-transporter 2 (SGLT2) inhibitors canagliflozin (Invokana, and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: SGLT2 Inhibitors and Renal Function
Article code: 1499a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.